Crispr Therapeutics AG (CRSPN) Stock Forecast & Price Target
1 Followers
CRSPN Analyst Ratings
Moderate Buy
8Buy6Hold0Sell
Based on 14 analysts giving stock ratings to Crispr Therapeutics AG in the past 3 months
CRSPN Stock 12 Month Forecast
Average Price Target
MXN 1,314.38▲(38.36% Upside)Based on 14 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is MXN 1,314.38 with a high forecast of MXN 2,041.16 and a low forecast of MXN 835.02. The average price target represents a 38.36% change from the last price of MXN 950.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 2.04K
AverageMXN 1.31K
LowMXN 835.02
Highest Price TargetHighestMXN 2,041.16Average Price TargetMXN 1,314.38Lowest Price TargetLowestMXN 835.02
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | MXN 1,484.48 | buy | 56.26%Upside | Reiterated | 11/04/26 | ||
| Yanan Zhu | Wells Fargo | MXN 1,391.70→MXN 1,298.92 | hold | 36.73%Upside | Assigned | 11/04/26 | ||
| Yigal Nochomovitz | Citi | MXN 1,632.93→MXN 1,670.04 | buy | 75.79%Upside | Reiterated | 11/04/26 | ||
| Alec Stranahan | Bank of America Securities | MXN 1,465.92→MXN 1,484.48 | buy | 56.26%Upside | Reiterated | 11/04/26 | ||
| Brian Cheng | J.P. Morgan | ― | buy | ― | Reiterated | 11/03/26 | ||
| Edward Tenthoff | Piper Sandler | MXN 2,041.16 | buy | 114.86%Upside | Reiterated | 11/03/26 | ||
| Joon Lee | UBS | MXN 964.91 | hold | 1.57%Upside | Reiterated | 11/03/26 | ||
| Luca Issi | RBC Capital | MXN 927.80 | hold | -2.34%Downside | Reiterated | 11/03/26 | ||
| Tyler Van Buren | TD Cowen | MXN 835.02 | hold | -12.10%Downside | Reiterated | 10/21/26 | ||
| Gil Blum | Needham | MXN 1,521.59 | buy | 60.17%Upside | Reiterated | 10/05/26 | ||
| Jonathan Miller | Evercore ISI | MXN 1,410.25 | buy | 48.45%Upside | Reiterated | 08/31/26 | ||
| Maxwell Skor | Morgan Stanley | MXN 1,113.36 | hold | 17.20%Upside | Reiterated | 08/28/26 | ||
| Sami Corwin | William Blair | ― | buy | ― | Reiterated | 08/28/26 | ||
| Salveen Richter | Goldman Sachs | MXN 890.69→MXN 1,020.58 | hold | 7.43%Upside | Assigned | 08/10/26 | ||
| Silvan Turkcan | Citizens JMP | MXN 1,484.48 | buy | 56.26%Upside | Reiterated | 07/22/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Mitchell KapoorH.C. Wainwright | BuyReiteratedMXN 1,484.48 | 11/04/26 | 56.26%Upside | ||
| Yanan ZhuWells Fargo | HoldAssignedMXN 1,391.70→MXN 1,298.92 | 11/04/26 | 36.73%Upside | ||
| Yigal NochomovitzCiti | BuyReiteratedMXN 1,632.93→MXN 1,670.04 | 11/04/26 | 75.79%Upside | ||
| Alec StranahanBank of America Securities | BuyReiteratedMXN 1,465.92→MXN 1,484.48 | 11/04/26 | 56.26%Upside | ||
| Brian ChengJ.P. Morgan | BuyReiterated | 11/03/26 | ― | ||
| Edward TenthoffPiper Sandler | BuyReiteratedMXN 2,041.16 | 11/03/26 | 114.86%Upside | ||
| Joon LeeUBS | HoldReiteratedMXN 964.91 | 11/03/26 | 1.57%Upside | ||
| Luca IssiRBC Capital | HoldReiteratedMXN 927.80 | 11/03/26 | -2.34%Downside | ||
| Tyler Van BurenTD Cowen | HoldReiteratedMXN 835.02 | 10/21/26 | -12.10%Downside | ||
| Gil BlumNeedham | BuyReiteratedMXN 1,521.59 | 10/05/26 | 60.17%Upside | ||
| Jonathan MillerEvercore ISI | BuyReiteratedMXN 1,410.25 | 08/31/26 | 48.45%Upside | ||
| Maxwell SkorMorgan Stanley | HoldReiteratedMXN 1,113.36 | 08/28/26 | 17.20%Upside | ||
| Sami CorwinWilliam Blair | BuyReiterated | 08/28/26 | ― | ||
| Salveen RichterGoldman Sachs | HoldAssignedMXN 890.69→MXN 1,020.58 | 08/10/26 | 7.43%Upside | ||
| Silvan TurkcanCitizens JMP | BuyReiteratedMXN 1,484.48 | 07/22/26 | 56.26%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Crispr Therapeutics AG
3 Months
Success Rate19/36 ratings generated profit
53%
Average Return
+9.70%
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 52.78% of your transactions generating a profit, with an average return of +9.70% per trade.
1 Year
Success Rate8/19 ratings generated profit
42%
Average Return
+6.88%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +6.88% per trade.
2 Years
Success Rate6/17 ratings generated profit
35%
Average Return
-1.49%
Copying Sami Corwin's trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -1.49% per trade.
CRSPN Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 7 | 6 |
| Buy | 7 | 8 | 7 | 7 | 3 |
| Hold | 6 | 8 | 7 | 9 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 25 | 22 | 23 | 15 |
In the current month, CRSPN has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CRSPN average Analyst price target in the past 3 months is 1,314.38.
CRSPN Financial Forecast
HighMXN -14.13
ConsensusMXN -22.12
LowMXN -40.31
CRSPN Earnings Forecast
Next quarter’s earnings estimate for CRSPN is -MXN 22.12 with a range of -MXN 40.31 to -MXN 14.13. The previous quarter’s EPS was -MXN 21.66. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 1.07B
ConsensusMXN 201M
LowMXN 0.00
CRSPN Sales Forecast
Next quarter’s sales forecast for CRSPN is MXN 200.98M with a range of MXN 0 to MXN 1.07B. The previous quarter’s sales results were MXN 238.65M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
CRSPN Stock Forecast FAQ
What is MX:CRSPN’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is Mex$1,314.38.
What is MX:CRSPN’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 38.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Crispr Therapeutics AG a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
What is Crispr Therapeutics AG’s share price target?
The average share price target for Crispr Therapeutics AG is Mex$1,314.38. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$2,041.16, and the lowest forecast is Mex$835.02. The average share price target represents a 38.36% increase from the current price of Mex$950.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Crispr Therapeutics AG?
To buy shares of MX:CRSPN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
